Smith Michael L, Nichols Daniel C, Underwood Paula, Fuller Zachary, Moser Matthew A, LoDico Charles, Gorelick David A, Newmeyer Matthew N, Concheiro Marta, Huestis Marilyn A
U.S. Army Forensic Toxicology Drug Testing Laboratory, Fort Meade, MD, USA.
Division of Workplace Programs, Substance Abuse Mental Health Services Administration, Department of Health and Human Services, Rockville, MD, USA.
Forensic Sci Int. 2014 Aug;241:87-90. doi: 10.1016/j.forsciint.2014.04.042. Epub 2014 May 14.
Opiates are an important component for drug testing due to their high abuse potential. Proper urine opiate interpretation includes ruling out poppy seed ingestion; however, detailed elimination studies after controlled poppy seed administration with known morphine and codeine doses are not available. Therefore, we investigated urine opiate pharmacokinetics after controlled oral administration of uncooked poppy seeds with known morphine and codeine content. Participants were administered two 45 g oral poppy seed doses 8 h apart, each containing 15.7 mg morphine and 3mg codeine. Urine was collected ad libitum up to 32 h after the first dose. Specimens were analyzed with the Roche Opiates II immunoassay at 2000 and 300 μg/L cutoffs, and the ThermoFisher CEDIA(®) heroin metabolite (6-acetylmorphine, 6-AM) and Lin-Zhi 6-AM immunoassays with 10 μg/L cutoffs to determine if poppy seed ingestion could produce positive results in these heroin marker assays. In addition, all specimens were quantified for morphine and codeine by GC/MS. Participants (N=22) provided 391 urine specimens over 32 h following dosing; 26.6% and 83.4% were positive for morphine at 2000 and 300 μg/L GC/MS cutoffs, respectively. For the 19 subjects who completed the study, morphine concentrations ranged from <300 to 7522 μg/L with a median peak concentration of 5239 μg/L. The median first morphine-positive urine sample at 2000 μg/L cutoff concentration occurred at 6.6 h (1.2-12.1), with the last positive from 2.6 to 18 h after the second dose. No specimens were positive for codeine at a cutoff concentration of 2000 μg/L, but 20.2% exceeded 300 μg/L, with peak concentrations of 658 μg/L (284-1540). The Roche Opiates II immunoassay had efficiencies greater than 96% for the 2000 and 300 μg/L cutoffs. The CEDIA 6-AM immunoassay had a specificity of 91%, while the Lin-Zhi assay had no false positive results. These data provide valuable information for interpreting urine opiate results.
由于阿片类药物具有很高的滥用潜力,因此是药物检测的重要组成部分。正确解读尿液阿片类药物检测结果包括排除罂粟籽摄入的影响;然而,目前尚无关于服用已知剂量吗啡和可待因的罂粟籽后详细的排泄研究。因此,我们研究了口服已知吗啡和可待因含量的生罂粟籽后尿液中阿片类药物的药代动力学。研究参与者分8小时间隔口服两次45克罂粟籽,每次含有15.7毫克吗啡和3毫克可待因。在首次服药后长达32小时内随意收集尿液。标本分别采用罗氏阿片类药物II免疫分析法,检测阈值为2000和300μg/L,以及赛默飞世尔公司的CEDIA(®)海洛因代谢物(6-乙酰吗啡,6-AM)和林芝6-AM免疫分析法,检测阈值为10μg/L,以确定摄入罂粟籽是否会在这些海洛因标记物检测中产生阳性结果。此外,所有标本均通过气相色谱/质谱法对吗啡和可待因进行定量分析。研究参与者(N = 22)在服药后32小时内提供了391份尿液标本;在气相色谱/质谱法检测阈值为2000和300μg/L时,分别有26.6%和83.4%的标本吗啡呈阳性。对于完成研究的19名受试者,吗啡浓度范围为<300至7522μg/L,中位峰值浓度为5239μg/L。在检测阈值浓度为2000μg/L时,首次出现吗啡阳性的尿液标本中位时间为6.6小时(1.2 - 12.1),第二次服药后最后一次阳性出现在2.6至18小时。在检测阈值浓度为2000μg/L时,没有标本可待因呈阳性,但20.2%的标本超过300μg/L,峰值浓度为658μg/L(284 - 1540)。罗氏阿片类药物II免疫分析法在检测阈值为2000和300μg/L时效率均大于96%。CEDIA 6-AM免疫分析法的特异性为91%,而林芝分析法未出现假阳性结果。这些数据为解读尿液阿片类药物检测结果提供了有价值的信息。